<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Definitions of SLE classification criteria</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Definitions of SLE classification criteria</h1>
<div class="graphic"><div class="figure"><div class="ttl">Definitions of SLE classification criteria</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup width="75%"></colgroup> <tbody> <tr> <td class="subtitle1">Criteria</td> <td class="subtitle1">Definition</td> </tr> <tr class="divider_bottom"> <td>Antinuclear antibodies (ANA)</td> <td>ANA at a titer of ≥1:80 on HEp-2 cells or an equivalent positive test at least once. Testing by immunofluorescence on HEp-2 cells or a solid phase ANA screening immunoassay with at least equivalent performance is highly recommended.</td> </tr> <tr class="divider_bottom"> <td>Fever</td> <td>Temperature &gt;38.3°C.</td> </tr> <tr class="divider_bottom"> <td>Leucopenia</td> <td>White blood cell count &lt;4.0 × 10<sup>9</sup>/L.</td> </tr> <tr class="divider_bottom"> <td>Thrombocytopenia</td> <td>Platelet count &lt;100 × 10<sup>9</sup>/L.</td> </tr> <tr class="divider_bottom"> <td>Autoimmune hemolysis</td> <td>Evidence of hemolysis, such as reticulocytosis, low haptoglobin, elevated indirect bilirubin, elevated lactate dehydrogenase (LDH) AND positive Coombs (direct antiglobulin) test.</td> </tr> <tr class="divider_bottom"> <td>Delirium</td> <td>Characterized by (1) change in consciousness or level of arousal with reduced ability to focus, (2) symptom development over hours to &lt;2 days, (3) symptom fluctuation throughout the day, (4) either (4a) acute/subacute change in cognition (eg, memory deficit or disorientation), or (4b) change in behavior, mood, or affect (eg, restlessness, reversal of sleep/wake cycle).</td> </tr> <tr class="divider_bottom"> <td>Psychosis</td> <td>Characterized by (1) delusions and/or hallucinations without insight and (2) absence of delirium.</td> </tr> <tr class="divider_bottom"> <td>Seizure</td> <td>Primary generalized seizure or partial/focal seizure.</td> </tr> <tr class="divider_bottom"> <td>Nonscarring alopecia</td> <td>Nonscarring alopecia observed by a clinician.*</td> </tr> <tr class="divider_bottom"> <td>Oral ulcers</td> <td>Oral ulcers observed by a clinician.*</td> </tr> <tr class="divider_bottom"> <td>Subacute cutaneous or discoid lupus</td> <td> <p>Subacute cutaneous lupus erythematosus observed by a clinician*: Annular or papulosquamous (psoriasiform) cutaneous eruption, usually photodistributed.</p> <p>Discoid lupus erythematosus observed by a clinician*: Erythematous-violaceous cutaneous lesions with secondary changes of atrophic scarring, dyspigmentation, often follicular hyperkeratosis/hematological (scalp), leading to scarring alopecia on the scalp.</p> If skin biopsy is performed, typical changes must be present. Subacute cutaneous lupus: interface vacuolar dermatitis consisting of a perivascular lymphohistiocytic infiltrate, often with dermal mucin noted. Discoid lupus: interface vacuolar dermatitis consisting of a perivascular and/or periappendageal lymphohistiocytic infiltrate. In the scalp, follicular keratin plugs may be seen. In longstanding lesions, mucin deposition and basement membrane thickening may be noted.</td> </tr> <tr class="divider_bottom"> <td>Acute cutaneous lupus</td> <td> <p>Malar rash or generalized maculopapular rash observed by a clinician.</p> If skin biopsy is performed, typical changes must be present: interface vacuolar dermatitis consisting of a perivascular lymphohistiocytic infiltrate, often with dermal mucin noted. Perivascular neutrophilic infiltrate may be present early in the course.</td> </tr> <tr class="divider_bottom"> <td>Pleural or pericardial effusion</td> <td>Imaging evidence (such as ultrasound, radiograph, CT scan, MRI) of pleural or pericardial effusion, or both.</td> </tr> <tr class="divider_bottom"> <td>Acute pericarditis</td> <td>≥2 of (1) pericardial chest pain (typically sharp, worse with inspiration, improved by leaning forward), (2) pericardial rub, (3) electrocardiogram (EKG) with new widespread ST-elevation or PR depression, (4) new or worsened pericardial effusion on imaging (such as ultrasound, radiograph, CT scan, MRI).</td> </tr> <tr class="divider_bottom"> <td>Joint involvement</td> <td>EITHER (1) synovitis involving 2 or more joints characterized by swelling or effusion OR (2) tenderness in 2 or more joints and at least 30 minutes of morning stiffness.</td> </tr> <tr class="divider_bottom"> <td>Proteinuria &gt;0.5 g/24 hours</td> <td>Proteinuria &gt;0.5 g/24 hours by 24 hours urine or equivalent spot urine protein-to-creatinine ratio.</td> </tr> <tr class="divider_bottom"> <td>Class II or V lupus nephritis on renal biopsy according to ISN/RPS 2003 classification</td> <td> <p>Class II: mesangial proliferative lupus nephritis: purely mesangial hypercellularity of any degree or mesangial matrix expansion by light microscopy, with mesangial immune deposit. A few isolated subepithelial or subendothelial deposits may be visible by immune-fluorescence or electron microscopy, but not by light microscopy.</p> Class V: membranous lupus nephritis: global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy and by immunofluorescence or electron microscopy, with or without mesangial alterations.</td> </tr> <tr class="divider_bottom"> <td>Class III or IV lupus nephritis on renal biopsy according to International Society of Nephrology/ Renal Pathology Society (ISN/RPS) 2003</td> <td> <p>Class III: focal lupus nephritis: active or inactive focal, segmental or global endocapillary or extracapillary glomerulonephritis involving &lt;50% of all glomeruli, typically with focal subendothelial immune deposits, with or without mesangial alterations.</p> Class IV: diffuse lupus nephritis: active or inactive diffuse, segmental or global endocapillary or extracapillary glomerulonephritis involving ≥50% of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial alterations. This class includes cases with diffuse wire loop deposits but with little or no glomerular proliferation.</td> </tr> <tr class="divider_bottom"> <td>Positive antiphospholipid antibodies</td> <td>Anticardiolipin antibodies (IgA, IgG, or IgM) at medium or high titer (&gt;40 A phospholipids [APL], GPL or MPL units, or &gt;the 99th percentile) or positive anti-beta-2GP1 antibodies (IgA, IgG, or IgM) or positive lupus anticoagulant.</td> </tr> <tr class="divider_bottom"> <td>Low C3 OR low C4</td> <td>C3 OR C4 below the lower limit of normal.</td> </tr> <tr class="divider_bottom"> <td>Low C3 AND low C4</td> <td>Both C3 AND C4 below their lower limits of normal.</td> </tr> <tr> <td>Anti-dsDNA antibodies OR anti-Smith (Sm) antibodies</td> <td>Anti-dsDNA antibodies in an immunoassay with demonstrated ≥90% specificity for SLE against relevant disease controls OR anti-Sm antibodies.</td> </tr> </tbody></table></div><div class="graphic_footnotes">SLE: systemic lupus erythematosus; HEp-2: human epithelial type 2; CT: computed tomography; MRI: magnetic resonance imaging; GP: glycoprotein; dsDNA: double-stranded DNA.<br/>* This may include physical examination or review of a photograph.</div><div class="graphic_reference">From: Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71(9):1400-1412. <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/art.40930" target="_blank">https://onlinelibrary.wiley.com/doi/full/10.1002/art.40930</a>. Copyright © 2019 American College of Rheumatology. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href="/cdn-cgi/l/email-protection#65150017080c16160c0a0b1625120c09001c4b060a08" target="_blank"><span class="__cf_email__" data-cfemail="5e2e3b2c33372d2d3731302d1e2937323b27703d3133">[email protected]</span></a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href="https://onlinelibrary.wiley.com/" target="_blank">https://onlinelibrary.wiley.com/</a>).</div><div id="graphicVersion">Graphic 122408 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
